Company intelligence / Profile preview

Helix Acquisition

Ownership: Private
Development stage: Other

Overview

Helix Acquisition Corp. II is a Special Purpose Acquisition Company (SPAC) that does not develop drugs or have its own pipeline of therapeutic modalities or targets. It is currently in the process of merging with BridgeBio Oncology Therapeutics. Upon completion of the merger, the combined entity will focus on advancing next-generation small molecule oncology therapeutics targeting RAS/PI3Kα-driven cancers.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Investors

Partnerships

Cormorant-led PIPE syndicate ($260M)BridgeBio Oncology Therapeutics (de-SPAC target)

Beyond the preview

Go deeper on Helix Acquisition.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Helix Acquisition.

Explore the full profile